Crossmark

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer

Published Online: 2021-02-27

Published Print: 2021-04

Authors

Garon, Edward B.

Brodrick, Paige
License Information

Text and Data Mining valid from 2021-02-27

Version of Record valid from 2021-02-27
More Information

Article History

Accepted: 3 February 2021

First Online: 27 February 2021

Declarations

:

: No external funding was used in the preparation of this manuscript.

: EBG has received research grants from Merck, Genentech, AstraZeneca, Novartis, Lilly, Bristol-Myers Squibb, Mirati Therapeutics, Dynavax, Iovance Biotherapeutics, Neon Therapeutics, and EMD Serono. EBG is an advisory board member of Dracen, EMD Serono, Novartis, GlaxoSmithKline, Merck, Boehringer Ingelheim, Shionogi, Eisai, and BMS. PB declares no conflicts of interest that might be relevant to the contents of this manuscript.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current